InsidersTradesSigma
Follow the Castle Biosciences INC share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Castle Biosciences INC has logged 491 public disclosures. Market capitalisation: €1bn. The latest transaction was filed on 3 September 2026 (Levée d'options). Among the most active insiders: MAETZOLD DEREK J. The full history is openly available.
491
Insider Decl.
n/a
Thresholds
€68,143
3 ops.
Buy Volume
€33m
359 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Castle Biosciences INC Strong Buy (bullish), based on 9 analysts. Average price target: US$44.00.
50Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 19,570 of 29,063 companies
40.4
score / 100
Value40
Quality41
FCF yld2.8%
Earn yld-2.4%
EV/EBITDA·
ROE-4.2%
Gross mgn79%
Net mgn-7.0%
Debt/EBITDA3.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 September 2026
Declarations491 total
4,152 shares@ US$3.380.0014% mcap0.3% of flowCommon StockSEC:0001628280-26-060430:0
3,952 shares@ US$33.360.013% mcap2.7% of flowCommon StockSEC:0001628280-26-060430:1
200 shares@ US$34.020.0007% mcap0.1% of flowCommon StockSEC:0001628280-26-060430:2
21 shares@ US$33.880.0001% mcap0.0% of flowCommon StockSEC:0001628280-26-059816:14
2,505 shares@ US$33.140.0082% mcap0.4% of flowCommon StockSEC:0001628280-26-059816:2
257 shares@ US$33.140.0008% mcap0.0% of flowCommon StockSEC:0001628280-26-059816:5
257 shares@ US$33.140.0008% mcap0.0% of flowCommon StockSEC:0001628280-26-059816:6
257 shares@ US$33.140.0008% mcap0.0% of flowCommon StockSEC:0001628280-26-059816:7
257 shares@ US$33.140.0008% mcap0.0% of flowCommon StockSEC:0001628280-26-059816:4
21 shares@ US$33.880.0001% mcap0.0% of flowCommon StockSEC:0001628280-26-059816:11
21 shares@ US$33.880.0001% mcap0.0% of flowCommon StockSEC:0001628280-26-059816:12
21 shares@ US$33.880.0001% mcap0.0% of flowCommon StockSEC:0001628280-26-059816:13
12,428 shares@ US$2.390.0029% mcap0.2% of flowCommon StockSEC:0001628280-26-059816:0
11,472 shares@ US$33.140.037% mcap2.0% of flowCommon StockSEC:0001628280-26-059816:1
2,129 shares@ US$33.140.0069% mcap0.4% of flowCommon StockSEC:0001628280-26-059816:3
956 shares@ US$33.880.0032% mcap0.2% of flowCommon StockSEC:0001628280-26-059816:8
209 shares@ US$33.880.0007% mcap0.0% of flowCommon StockSEC:0001628280-26-059816:9
177 shares@ US$33.880.0006% mcap0.0% of flowCommon StockSEC:0001628280-26-059816:10
9,050 shares@ US$35.040.030% mcap13.7% of flowCommon StockSEC:0001628280-26-059272:0
12,218 shares@ US$33.6870.038% mcap8.7% of flowCommon StockSEC:0001628280-26-059091:0
7,161 shares@ US$34.2630.023% mcap5.2% of flowCommon StockSEC:0001628280-26-059091:1
5,223 shares@ US$34.6390.017% mcap3.8% of flowCommon StockSEC:0001628280-26-059091:2
1,730 shares@ US$29.590.0056% mcap2.6% of flowCommon StockSEC:0001628280-26-057949:0
1,100 shares@ US$30.020.0036% mcap0.2% of flowCommon StockSEC:0001628280-26-057642:1
1,100 shares@ US$2.390.0003% mcap0.0% of flowCommon StockSEC:0001628280-26-057642:0
25 of 491 declarations
关于 Castle Biosciences INC
Castle Biosciences, Inc. (NASDAQ: CSTL) 是一家总部位于美国德克萨斯州弗兰兹伍德的美国分子诊断公司。对于法语投资者而言，它是一家专注于预后和诊断测试的医疗保健专业公司，旨在改善具有重大未满足医疗需求的领域的治疗决策。该公司由Derek Maetzold于2007年创立，他至今仍担任其总裁兼首席执行官。其商业模式围绕专有的实验室开发测试构建，旨在提供源自肿瘤生物学和相关分子特征的临床可操作信息。 Castle的传统和仍然是核心业务的特许经营权是皮肤肿瘤学。其万博体育app下载官网组合包括DecisionDx-Melanoma、DecisionDx-SCC和MyPath Melanoma，旨在帮助临床医生为患有皮肤黑色素瘤、皮肤鳞状细胞癌和可疑色素病变的患者完善风险评估。该公司还通过TissueCypher将业务从皮肤癌扩展到胃肠病学，该测试用于识别进展为食管癌风险较高的巴雷特食管患者。最近，Castle推出了AdvanceAD-Tx，以支持中度至重度特应性皮炎的全身治疗决策，这突显了其将特许经营权扩展到邻近高价值疾病领域的战略。 从竞争角度来看，Castle将自己定位为高实用性分子检测领域的专业公司，其区别在于临床证据和医生采纳，而非仅仅规模。该公司强调了大量的同行评审出版物和不断积累的真实世界数据，这些数据支持其测试相对于传统病理学或分期方法的临床有效性和实用性。在运营方面，其业务仍以美国为中心，在凤凰城和匹兹堡设有临床实验室，并在弗兰兹伍德设有新的公司总部。这种设置支持商业化和实验室执行，同时使公司与美国临床医生和支付方动态保持紧密联系。 近期发展突显了势头的改善。在2026年第一季度，Castle报告收入为83.7百万美元，并将2026年全年收入指引上调至345-355百万美元，反映出其核心增长驱动力DecisionDx-Melanoma和TissueCypher的强劲表现。该公司还宣布于2026年3月在弗兰兹伍德新总部盛大开业，这是对基础设施和产能进行长期投资的标志。对于投资者而言，CSTL提供了对纳斯达克上市的美国诊断平台的投资机会，该平台拥有专业的增长特许经营权，但也伴随着与报销、监管审查以及需要不断证明临床和经济价值相关的常见风险。
